Oncology and Carcinogenesis articles for Spain

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 290

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 0.31
Scavenging Reactive Oxygen Species by Cerium Oxide Nanoparticles Prevents Death in a Peripheral T Cell Lymphoma Preclinical Mouse Model 0.31
2 1.57
Ultrasmall Platinum Nanoparticles for Radiation‐Enhanced Cancer Therapy 1.00
Plasma-Treated Hydrogel for Combined RONS and Chemotherapy Delivery: A Proof-of-Concept In Ovo 0.57
3 1.94
Bi-Functional Topospecific Nanoparticles to Promote Immune-Tumor Cell Engagement as A New Immunotherapeutic Strategy 1.00
An Intracellular Magnetic Micromotor Drives Spatiotemporal Mechano‐Immunotherapy 0.04
Bioorthogonal Photoactivation of 2-Nitrobenzyl Caged Doxorubicin Anticancer Prodrugs on Gold Nanostars 0.91
2 0.13
Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention 0.03
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes 0.10
1 0.05
A trans-omics gene-smoking interaction study of lung cancer based on consortium data 0.05
1 0.07
Probing Field Cancerization in the Gastrointestinal Tract Using a Hybrid Raman and Partial Wave Spectroscopy Microscope 0.07
4 1.13
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.02
Setting the Standard in Robotic Whipple Surgery: International Multicenter Benchmark Analysis. 0.03
Blumgart Anastomosis Versus Invaginating Pancreato-gastrostomy For Reconstruction After Pancreatoduodenectomy: A Randomized Controlled Trial. 1.00
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.08
1 0.08
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus 0.08
10 1.95
Immune biomarkers of increased infection risk in multiple myeloma 0.67
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.03
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma 0.02
Dose-dense chemotherapy enables elimination of RT for the majority of low-risk pediatric Hodgkin lymphomas: PHC study HOD08 0.02
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.03
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.14
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.02
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment 0.95
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells 0.02
1 0.02
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study 0.02
3 1.90
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer 0.05
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak 1.00
Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception 0.85
7 3.64
The Histone Methyltransferase KMT2D is a Critical Mediator of Lineage Plasticity and Therapeutic Response in Castration Resistant Prostate Cancer 0.03
KDM6 Demethylases Contribute to EWSR1::FLI1-Driven Oncogenic Reprogramming in Ewing Sarcoma 0.95
In Silico Digital Twins of Bone Metastasis Enable Investigation of Tumor Progression and Therapy Response 0.40
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy 1.00
Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma 0.05
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer 0.85
Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy 0.36
2 1.80
Insights into type I photoreactivity of cyclometalated iridium(iii) and ruthenium(ii) photosensitizers 1.00
A snapshot of flavin-conjugated Pt anticancer agents: Pt(iv)-to-Pt(ii) reduction revealed by X-ray fluorescence imaging and XANES 0.80
1 0.33
Glycofullerene–corrole hybrids: a new class of multifunctional nanomaterials with potential in targeted photodynamic therapy 0.33
2 1.17
Linking Lungs and Heart 0.17
KRAS Mutation Status in NSCLC: Distribution across Occupational Categories 1.00
1 0.92
Centrosome clustering in cancer cells requires microtubule assembly through a RanGTP-dependent TPX2-KIFC1 interaction 0.92
1 0.04
Oxidative damage, genetic and epigenetic alterations in hexavalent chromium exposed workers - A cross-sectional study within the SafeChrom project 0.04
1 1.00
LRP5, a WNT signalling pathway receptor, and platelet activation 1.00
1 0.10
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial 0.10
1 0.90
An Exosome-Based Liquid Biopsy for the Detection of Early-Onset Colorectal Cancer: The ENCODER Multicenter Study 0.90
6 4.19
Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy 0.98
Effect of long-term adherence on faecal immunochemical test positivity rate, positive predictive value and detection rate in organised population-based colorectal cancer screening 0.88
Simvastatin in the prevention of recurrent pancreatitis: a triple-blinded randomised clinical trial (the SIMBA trial) 0.84
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.13
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential 0.76
A fusion-based deep-learning algorithm predicts PDAC metastasis based on primary tumour CT images: a multinational study 0.62
5 1.76
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.05
Hepatocellular carcinoma with macrovascular invasion: Review and survival meta-analysis of initial local therapy using minimal prognostic criteria. 0.73
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway. 0.73
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement. 0.18
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. 0.07
1 0.13
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.13
2 1.29
Dual-Action NSAID-Gold(I) Alkynyl Hybrids for Synergistic Anti-Inflammatory and Anticancer Therapy of Colorectal Cancer 1.00
Substrate-Mimicking Peptides as MMP-1 Inhibitors: Impact of Zinc-Binding Group Position on Ternary Complex Stability 0.29
2 0.40
Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project 0.25
Body mass index and gastric cancer risk: results from the Stomach Cancer Pooling Project Consortium 0.15
1 1.00
Chemoradiotherapy and Local Excision vs Total Mesorectal Excision in T2-T3ab, N0, M0 Rectal Cancer 1.00
1 0.06
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.06
1 0.43
Cholesterol promotes the formation of dimers and oligomers of the receptor tyrosine kinase ROR1 0.43
1 0.29
Effect of Timing of First Consultation with a Sarcoma Specialist Following Unplanned Excision: Oncologic Outcomes of Patients with Soft-Tissue Sarcomas. 0.29
1 0.17
Roles of Srs2/PARI-family DNA helicases in NoCut checkpoint signaling and abscission regulation 0.17
1 1.00
Integrating Artificial Intelligence in Thyroid Nodule Management: Clinical Outcomes and Cost-effectiveness Analysis 1.00
5 1.14
Estrogen Receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer 0.91
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma 0.07
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.08
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.02
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.05
41 5.86
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.09
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.19
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors. 0.11
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.05
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.04
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in BRCA1 or BRCA2. 0.04
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm. 0.04
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.33
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. 0.02
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.08
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer. 0.11
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. 0.11
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. 0.20
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.14
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.03
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.14
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.26
Ifinatamab Deruxtecan in Patients With Extensive-Stage Small-Cell Lung Cancer: Primary Analysis of the Phase 2 IDeate-Lung01 Trial. 0.13
Quizartinib for Newly Diagnosed FLT3-ITD-Negative Acute Myeloid Leukemia: The Randomized, Double-Blind, Placebo-Controlled, Phase 2 QUIWI Study. 1.00
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.13
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). 0.19
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.05
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. 0.28
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.12
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.09
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.27
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.09
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.04
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.03
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203. 0.69
Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non-Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy. 0.05
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.06
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.04
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab. 0.12
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. 0.13
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.08
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.14
Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database. 0.05
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. 0.06
4 1.60
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 0.21
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.06
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 0.43
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas 0.90
1 0.07
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.07
2 0.80
Manganese-Templated Nontrivial Structures for MRI and Therapy 0.05
π-Extended Ru–COUBPY Photosensitizers for In Vivo Anticancer Phototherapy Using One-Photon 780 nm Near-Infrared Light 0.75
10 2.23
EHealth intervention for quality of life in long-term breast cancer survivors: Randomized controlled trial 1.00
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.04
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.04
Frequency and clinical features of germline pathogenic variants in sarcoma: a case-control study 0.03
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Assessing Outcomes Emerging After Conversion to Regular Approval for Cancer Drug Indications Granted Accelerated Approval, 1992-2021 0.25
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC 0.05
Breastfeeding after breast cancer in young iBRCA/i carriers 0.02
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.03
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer 0.75
3 0.38
Structural basis for TORC2 activation 0.17
BRCA2-dependent maturation of nascent strands during DNA replication 0.13
CRAMP1-dependent histone H1 biogenesis is essential for topoisomerase II inhibitor tolerance 0.09
1 1.00
Nanomotor-Assisted Intravesical Chemotherapy for Bladder Tumor Reduction and Suppression of Early Tumor Regrowth 1.00
9 1.37
A pro-carcinogenic bacterial toxin binds claudin-4 to cleave E-cadherin 0.14
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.03
Ancestry and somatic profile indicate acral melanoma origin and prognosis 0.03
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.04
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.02
Sex and smoking bias in the selection of somatic mutations in human bladder 0.59
Fluctuating DNA methylation tracks cancer evolution at clinical scale 0.48
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.02
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.03
1 0.01
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability 0.01
1 0.03
ZBTB11 depletion targets metabolic vulnerabilities in KRAS inhibitor-resistant PDAC 0.03
45 17.67
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.24
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer 0.02
Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial 0.13
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial 0.13
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial 0.98
Genomic analysis of T Cell receptors reveals lynch syndrome specific immune signatures 0.21
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.03
Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment 0.07
Proteostasis failure and mitochondrial dysfunction contribute to chromosomal instability-induced microcephaly 1.00
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer 0.07
A hormetic transcriptional program coregulates invasion, proliferation and dormancy to define metastatic potential 1.00
Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis 0.71
Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO) 0.88
Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression 0.17
Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study 1.00
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis 0.04
Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases 0.86
Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial 1.00
A recurrent pathogenic truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription 0.17
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
Metabolic support protects mucosa from ferroptosis in radiation-induced mucositis 0.07
Glasdegib in combination with temozolomide and radiotherapy in adult patients with newly diagnosed glioblastoma: the phase Ib/II GEINO 1602 trial 1.00
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.66
Palbociclib and endocrine therapy diminish adaptive anti-tumor immunity in early breast cancer: The NeoRHEA phase 2 study 0.09
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma 0.08
Human iPSCs-based modeling unveils SETBP1 as a driver of chromatin rewiring in GATA2 deficiency 0.89
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.06
PRKG1 hinders myogenic differentiation and predicts response to AKT inhibitor ipatasertib in Rhabdomyosarcoma 1.00
HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy 0.45
EWS::FLI1 expression in human embryonic mesenchymal stem cells leads to transcriptional reprograming, defective DNA damage repair and Ewing sarcoma 0.98
Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci 0.02
The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia 0.03
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.03
In vivo CRISPR screening in head and neck cancer reveals as an immunotherapy target 0.01
Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors 0.11
High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models 1.00
Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing 0.82
A -natural antisense RNA regulates alternative polyadenylation of under Pi starvation in tomato 0.08
Splicing QTL mapping in stimulated macrophages associates low-usage splice junctions with immune-mediated disease risk 0.03
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.07
The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations 0.28
Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response 0.02
Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity 0.84
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression 0.17
Alectinib in combination with bevacizumab as first-line treatment in -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial 0.08
4 0.15
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.01
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.06
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.06
Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption 0.02
1 1.00
Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia 1.00
20 4.61
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial 0.08
Epigenetic fingerprints link early-onset colon and rectal cancer to pesticide exposure 1.00
Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial 0.02
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial 0.26
Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trial 0.04
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.14
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.13
AI-based triage and decision support in mammography and digital tomosynthesis for breast cancer screening: a paired, noninferiority trial 0.80
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.01
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.08
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.15
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 0.88
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial 0.08
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial 0.10
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial 0.61
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer 0.06
2 1.10
Structure and function of the yeast amino acid-sensing SEAC–EGOC supercomplex 0.10
Core splicing architecture and early spliceosomal recognition determine microexon sensitivity to SRRM3/4 1.00
1 0.07
Adolescent cardiorespiratory fitness and risk of cancer in late adulthood: A nationwide sibling-controlled cohort study in Sweden 0.07
6 3.34
The antimetastatic effects of calorie restriction are negated by voluntary exercise in an aggressive breast cancer mouse model 0.18
A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance 0.92
Isoform-specific regulation of PKM by acetylation 0.29
The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche 0.01
Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice 0.95
Massive mutagenesis reveals an incomplete amyloid motif in Bri2 that turns amyloidogenic upon C-terminal extension 1.00
1 0.13
Tumor Involvement of the Nipple at Preoperative Contrast-enhanced Mammography: A Multicenter Diagnostic Accuracy Study. 0.13
1 0.01
A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis 0.01
5 0.75
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis 0.05
Tuning of the RBR1-E2F/DP transcriptional module by the F-box protein FBL17 0.11
Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment 0.01
Human iPSC-based breast cancer model identifies S100P-dependent cancer stemness induced by BRCA1 mutation 0.03
Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation 0.55
4 0.81
Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer 0.05
Homeostatic control of energy metabolism by monocyte-derived macrophages 0.10
Concurrence of mutations modulates oncogenesis in glioneuronal tumors 0.57
Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer 0.09
11 0.98
Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial 0.12
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.11
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.11
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.12
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.14
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial 0.05
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial 0.11
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial 0.07
19 3.48
Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial 0.08
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.13
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.07
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.03
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial 0.62
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial 0.44
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.13
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial 0.50
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.16
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.07
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis 0.58
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study 0.05
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study 0.04
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study 0.06
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study 0.02
Zanidatamab plus palbociclib and fulvestrant in previously treated patients with hormone receptor-positive, HER2-positive metastatic breast cancer: primary results from a two-part, multicentre, single-arm, phase 2a study 0.37
24 1.72
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.08
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer 0.06
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.04
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.10
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.03
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.09
Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab 0.09
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.09
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.05
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.13
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.05
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.10
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.10
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.04
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.06
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.07
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.08
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.08
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.07
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.04
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.07
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer 0.10

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.